Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy


Kister I., Spelman T., Patti F., Duquette P., Trojano M., Izquierdo G., ...Daha Fazla

JOURNAL OF THE NEUROLOGICAL SCIENCES, cilt.391, ss.72-76, 2018 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 391
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1016/j.jns.2018.06.001
  • Dergi Adı: JOURNAL OF THE NEUROLOGICAL SCIENCES
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.72-76
  • Anahtar Kelimeler: Multiple sclerosis, Relapse, Disability, Disease modifying therapy, Observational cohort study, MULTIPLE-SCLEROSIS, FINGOLIMOD TREATMENT, NATALIZUMAB, WITHDRAWAL, CESSATION, COHORT
  • Karadeniz Teknik Üniversitesi Adresli: Evet

Özet

Background: Discontinuation of disease-modifying therapies (DMTs) for MS is common. MSBase, a large global observational registry, affords a unique opportunity to investigate predictors of 'post-DMT' relapses and confirmed disability progression (CDP) in a diverse group of patients exposed to different DMTs.